Hidradenitis Suppurativa Companies

ID: MRFR/Pharma/2497-HCR

68 Pages

Satyendra Maurya

Last Updated: February 16, 2025

Hidradenitis Suppurativa (HS) is a chronic skin condition characterized by the formation of painful nodules, abscesses, and tunnels under the skin, typically in areas where skin rubs together. While there is no cure for HS, various pharmaceutical companies are actively involved in researching and developing treatments to manage symptoms and improve the quality of life for individuals with this condition.

Hidradenitis Suppurativa Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.72%

2024 Market Size$ 0.66 Billion

2025 Market Size$ 0.69 Billion

2035 Market Size$ 1.1 Billion

Key Players

AbbVie

Amgen

Janssen Pharmaceuticals

Novartis

Boehringer Ingelheim

Eli Lilly and Company

Trends

Rising Awareness and Diagnosis
Shift Towards Biologic Treatments
Emphasis on Personalized Medicine

Opportunities

Rising Healthcare Expenditure
Advancements in Treatment Modalities
Integration of Telemedicine in Dermatology

Summary Table of Contents Segmentation Methodology Download PDF

Customize Report

Certified Researchers

Top Industry Leaders in the Hidradenitis Suppurativa Market

Latest Hidradenitis Suppurativa Companies Update

Positive Phase 3 results for bimekizumab (Sun Pharma): December 2023 saw promising news with BE HEARD I and II trials demonstrating significant improvements in pain and overall disease activity in HS patients treated with bimekizumab. This could lead to a new biologic option for moderate-to-severe HS.

Secukinumab (Novartis) emerges as a leading treatment: October 2023 research confirms Secukinumab's increasing adoption by dermatologists, solidifying its position as a key player in the HS treatment landscape.

AbbVie initiates Phase 2 trial for Upadacitinib: January 2024 news brings us another potential contender, with AbbVie investigating Upadacitinib, a JAK inhibitor, for HS treatment.

FDA approves intravenous Cosentyx (Novartis) for HS: June 2023 approval offers a new administration option for this biologic, potentially improving convenience for some patients.

List of Hidradenitis Suppurativa Key Companies in the Market

AstraZeneca (UK)
Pfizer Inc.(US)
GlaxoSmithKline plc. (UK)
Merck & Co., Inc. (US)
Johnson & Johnson Services Inc. (US)

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”